ESMO Events 2025

Meetings 新しいタブ／ウィンドウで開く | ESMO 新しいタブ／ウィンドウで開く

Welcome to our ESMO Virtual Congress site where we showcase the very best from ESMO's flagship portfolio.

ESMO Sarcoma and Rare Cancers Congress 2025 新しいタブ／ウィンドウで開く

Whether you are a seasoned oncologist, a dedicated researcher, a healthcare professional, a pharmaceutical industry leader, or a patient advocate, this event offers something for everyone committed to advancing the care and improving outcomes of patients with sarcomas and rare cancers. Below a collection of papers recently published in ESMO’s premier journals carefully selected to reflect the themes of the meeting.

Annals of Oncology

• A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse 新しいタブ／ウィンドウで開く J.-Y. Blay; C. Schiffler; O. Bouché; M. Brahmi; F. Duffaud; M. Toulmonde; B. Landi; W. Lahlou; D. Pannier; E. Bompas; F. Bertucci; L. Chaigneau; O. Collard; M. Pracht; C. Henon; I. Ray-Coquard; K. Armoun; S. Salas; M. Spalato-Ceruso; A. Adenis; B. Verret; N. Penel; C. Moreau-Bachelard; A. Italiano; A. Dufresne; S. Metzger; S. Chabaud; D. Perol; A. Le Cesne

• Results of a phase Ib study of olaparib with concomitant radiotherapy in soft-tissue sarcoma: a French sarcoma group study 新しいタブ／ウィンドウで開く P. Sargos, MD; M.P. Sunyach, MD; A. Ducassou, MD; C. Llacer, MD; D. Dinart, PhD; A. Michot, MD; T. Valentin, MD; N. Firmin, MD; J.Y. Blay, MD PhD; P. Gillon, MD; C. Bellera, PhD; A. Italiano, MD PhD

ESMO Open

• Efficacy, safety, and pharmacokinetics of eribulin as monotherapy or in combination with irinotecan for patients with pediatric rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, or Ewing sarcoma 新しいタブ／ウィンドウで開く M. Casanova; C.M. Albert; F. Bautista; S.C. Borinstein; S. Bradfield; A. Bukowinski; Q. Campbell-Hewson; D.S. Hawkins; A. Kim; G.M. Milano; L.V. Marshall; N. Pinto; C.A. Pratilas; A. Rubio-San-Simón; R. Windsor; O. Majid; R. Scott; Y. Jia; C. Paoletti; U. Kontny

• Genomic profiling of intimal sarcoma reveals molecular subtypes with distinct tumor microenvironments and therapeutic implications 新しいタブ／ウィンドウで開く C. Park; R. Kim; J.M. Bae; T. Lee; S. Song; Y. Kwak; K.B. Lee; J. Youk; B. Keam; T.M. Kim; D.-W. Kim; J.-I. Kim; J. Choi; M. Kim

Immuno-Oncology and Technology

• Armoring chimeric antigen receptor (CAR) T cells as micropharmacies for cancer therapy 新しいタブ／ウィンドウで開く C. Carcopino; E. Erdogan; M. Henrich; S. Kobold

• Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma 新しいタブ／ウィンドウで開く T.J. Monberg; T. Kudling; B. Albieri; S. Pakola; E. Ellebaek; M. Donia; R.L. Eefsen; C. von Buchwald; C. Kistler; J.M. Santos; J. Clubb; L. Haybout; M.C.W. Westergaard; D.C.A. Quixabeira; E. Jirovec; R. Havunen; S. Sorsa; V. Cervera-Carrascon; A. Hemminki; I.M. Svane

ESMO Gastrointestinal Oncology

• Gastrin-releasing peptide receptor expression in gastrointestinal stromal tumours 新しいタブ／ウィンドウで開く M. Berndsen; F. Puls; A. Thornell; Y. Arvidsson; A. Muth; S. Lindskog; E. Elias

• Exploring the pathway: clinical utility and open challenges of targeting BRAF alterations in biliary tract cancers and gastrointestinal malignancies 新しいタブ／ウィンドウで開く L. Weiss; D. Zhang; W.G. Kunz; S. Boeck; G. Curigliano; V. Subbiah; F. Lordick; T. Brummer; C.B. Westphalen; L. Boscolo Bielo

ESMO Real World Data and Digital Oncology

• Real-world treatment patterns and challenges of patients with biliary tract cancer: retrospective chart review survey in Europe (GARNET-2) 新しいタブ／ウィンドウで開く J. Bridgewater; J. Sah; A. Szende; M. Paskow; P. Messina; B. Baur; J.M. Banales

• Head and Neck Sarcoma Assessor (HaNSA) for treatment decisions using real-world data 新しいタブ／ウィンドウで開く M.Y.S. See; J.J.N. Goh; C.E. Low; C.E. Yau; W.S. Ong; R.X. Wong; N.F. Mohamed Noor; M.H.B.H. Mohamed; J.T. Suha; A.N.H. Sairi; W.L. Goh; X.Y. Woo; V.S. Yang

ESMO affiliated journals

• Neoadjuvant chemotherapy for radiation associated angiosarcoma (RAAS) of the breast: A retrospective single center study 新しいタブ／ウィンドウで開く Stijn J.C. van der Burg; Sophie J.M. Reijers; Anke Kuijpers; Lotte Heimans; Astrid N. Scholten; Rick L.M. Haas; Hester van Boven; Willemijn M. Kolff; Marie-Jeanne T.F.D. Vrancken Peeters; Martijn Kerst; Beatrijs A. Seinstra; Neeltje Steeghs; Winette T.A. van der Graaf; Yvonne M. Schrage; Winan J. van Houdt

• Personalized treatment strategies for breast adenoid cystic carcinoma: A machine learning approach 新しいタブ／ウィンドウで開く Sakhr Alshwayyat; Mahmoud Bashar Abu Al Hawa; Mustafa Alshwayyat; Tala Abdulsalam Alshwayyat; Siya sawan; Ghaith Heilat; Hanan M. Hammouri; Sara Mheid; Batool Al Shweiat; Hamdah Hanifa

• Functioning neuroendocrine tumors (NET): Minimum requirements for a NET specialist 新しいタブ／ウィンドウで開く F. Spada; R.E. Rossi; R. Modica; F. Gelsomino; M. Rinzivillo; M. Rubino; E. Pisa; A.La Salvia; N. Fazio

• Primary mediastinal large B-cell Lymphoma: Biological features, clinical characteristics and current treatment strategies 新しいタブ／ウィンドウで開く Livia Donzelli; Alice Di Rocco; Luigi Petrucci; Maurizio Martelli

• Primary pulmonary adenoid cystic carcinoma: A study of clinicopathological features and molecular alterations in twenty-one cases 新しいタブ／ウィンドウで開く Zhiyuan Yao; Tong Qiu; Changlei Li; Weimao Kong; Guangqi Li; Peng Song; Guohua Wang; Wenjie Jiao

• Efficacy of immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma and predictive potential of mutated TP53 新しいタブ／ウィンドウで開く Mingying Wu; Na Zhou; Mei Guan; Yingyi Wang; Yuzhou Wang

• Clinical Impact of Next-Generation Sequencing of T-Cell Lymphomas: A Single Institution Experience 新しいタブ／ウィンドウで開く Omar Elghawy; Julia Wang; Olivia J. Leung; Nishwant Swami; Veronica Carvajal; Guang Yang; Daniel J. Landsburg; Jakub Svoboda; Sunita D. Nasta; Elise A. Chong; Stephen J. Schuster; Colin J. Thomas; Jordan S. Carter; Adam Bagg; Stefan K. Barta

• A Real-World Evaluation of Frontline Treatment for Acute Myeloid Leukemia With Azacitidine Plus Venetoclax 新しいタブ／ウィンドウで開く Joseph Brandwein; David Page; Elena Liew; Mark Hnatiuk; Lauren Bolster; Marlene Hamilton; Daniel Sawler; Peng Wang

ESMO's Journal Portfolio

While diverse in nature and in content, these journals offer ESMO members and the oncology community a highly visible platform to publish important scientific studies, and a highly credible source for educational updates. Elsevier is the proud publisher of Annals of Oncology, Immuno-Oncology and Technology (IOTECH), ESMO Open, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology, ESMO Rare Cancers, and ESMO Affiliated Journals The Breast, Lung Cancer, Cancer Treatment Reviews and Clinical Lymphoma Myeloma and Leukemia.